K083080 is an FDA 510(k) clearance for the IGX PLEX RHEUMATOID ARTHRITIS (RA) ASSAY AND SQIDWORKS DIAGNOSTICS PLATFORM. Classified as System, Test, Rheumatoid Factor (product code DHR), Class II - Special Controls.
Submitted by Sqi Diagnostics Systems (Toronto, On, CA). The FDA issued a Cleared decision on October 29, 2009 after a review of 378 days - an unusually long review period, suggesting complex equivalence evaluation.
This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5775 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.
View all Sqi Diagnostics Systems devices